Edwin del Rosario
Internal Medicine · Keller, TXNPI 1124087440
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 169 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,895 and has fallen 97.9% since, to $40 in 2023.
Across 169 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$379
- Medicure Pharma Inc.$306
- AbbVie$262
- Lilly USA, LLC$228
- Medtronic$189
- Boehringer Ingelheim$185
- plus $2K from 22 others
What the payments were for
- Consulting fees$60%
- Food & beverage$3,220100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 13 | $379 |
| Medicure Pharma Inc. | 3 | $306 |
| AbbVie(2 entities) | 20 | $262 |
| Lilly USA, LLC | 17 | $228 |
| Medtronic(3 entities) | 6 | $189 |
| Boehringer Ingelheim | 10 | $185 |
| Kvk-tech, Inc. | 8 | $164 |
| Amgen | 9 | $146 |
| Amarin Pharma, Inc. | 17 | $145 |
| Optinose US, Inc. | 7 | $142 |
| Biohaven Pharmaceuticals, Inc. | 7 | $137 |
| Arbor Pharmaceuticals, Inc. | 8 | $120 |
| AstraZeneca | 5 | $112 |
| Eisai Inc. | 5 | $94 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $94 |
| GSK | 5 | $78 |
| Amneal Pharmaceuticals LLC | 5 | $73 |
| Genentech USA, Inc. | 4 | $68 |
| Sanofi-aventis U.S. LLC | 3 | $42 |
| Esperion Therapeutics, Inc. | 3 | $41 |
| Abbott | 2 | $40 |
| Avanos Medical | 1 | $36 |
| Upsher-smith Laboratories LLC | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Currax Pharmaceuticals LLC | 2 | $27 |
| Valeritas, Inc. | 2 | $25 |
| Dexcom, Inc. | 1 | $18 |
| Boston Scientific | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HMG-CoA reductase inhibitor.$279
- Wegovy$113
- Saxenda$112
- AQUAMANTYS$105
How this compares
$3,227 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Keller
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.